| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5689228 | European Urology | 2017 | 9 Pages |
Abstract
Patients with metastatic prostate cancer and germline DNA repair defects exhibit a poor response to standard hormonal therapies, but may be prioritized for potentially more effective therapies using a blood test.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Matti Annala, Werner J. Struss, Evan W. Warner, Kevin Beja, Gillian Vandekerkhove, Amanda Wong, Daniel Khalaf, Irma-Liisa Seppälä, Alan So, Gregory Lo, Rahul Aggarwal, Eric J. Small, Matti Nykter, Martin E. Gleave, Kim N. Chi, Alexander W. Wyatt,